Bio

Dr. Jeffrey Bryan earned a Bachelor of Science degree in veterinary science from the University of California - Davis in 1991.  He received his D.V.M. from the University of California - Davis in 1993. He worked as an Associate Veterinarian from 1993-1995 and served as Medical Director from 1995-2002 of the Irving Street Veterinary Hospital in San Francisco, CA.  Bryan then completed a medical oncology residency, a Masters of Biomedical Sciences, and a PhD in Pathobiology at the University of Missouri.  He received certification by the American College of Veterinary Internal Medicine in Oncology 2005.  He is the Director of the Tom and Betty Scott Endowed Program in Veterinary Oncology, the Comparative Oncology Radiobiology and Epigenetics Laboratory, and the PET Imaging Center of the University of Missouri.   Dr. Bryan’s research focuses on comparative examination of cancers in companion animals to better understand cancers in all species. His particular areas of interest are targeted imaging and therapy and epigenetics of cancer.

Abstract

Autologous Activated T cell Therapy for Osteosarcoma of Companion Dogs

Canine osteosarcoma (OSA) is an aggressively metastatic primary bone malignancy with frequent chemotherapy failure. We hypothesized that dogs with OSA would be safely treated with autologous vaccination, adoptive T cell transfer (ACT) of ex vivo-activated T cells and low dose human interleukin-2 (IL-2) resulting in improved survival compared to carboplatin.